Generation Bio Co has a quick ratio of 5.50. It generally indicates good short-term financial strength.
The historical rank and industry rank for Generation Bio Co's Quick Ratio or its related term are showing as below:
GBIO'
s Quick Ratio Range Over the Past 10 Years
Min: 1.98 Med: 11.74 Max: 23.86
Current: 5.5
During the past 7 years, Generation Bio Co's highest Quick Ratio was 23.86. The lowest was 1.98. And the median was 11.74.
GBIO's Quick Ratio is ranked better than 66.64% of 1496
companies
in the Biotechnology industry
Industry Median: 3.38
vs GBIO: 5.50
Generation Bio Co Quick Ratio Historical Data
The historical data trend for Generation Bio Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Generation Bio Co's Quick Ratio
For the Biotechnology subindustry, Generation Bio Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Generation Bio Co's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Generation Bio Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Generation Bio Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Generation Bio Co's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generation Bio Co (NAS:GBIO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Generation Bio Co Quick Ratio Related Terms
Thank you for viewing the detailed overview of Generation Bio Co's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GBIO has been successfully added to your 